These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3204621)

  • 1. Overview of different logistical approaches to postmarketing surveillance.
    Strom BL
    J Rheumatol Suppl; 1988 Oct; 17():9-13. PubMed ID: 3204621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing surveillance and other epidemiologic uses of drug prescription data in the United States.
    Strom BL
    Ann Ist Super Sanita; 1991; 27(2):235-7. PubMed ID: 1755576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing surveillance for human teratogenicity: a model approach.
    Chambers CD; Braddock SR; Briggs GG; Einarson A; Johnson YR; Miller RK; Polifka JE; Robinson LK; Stepanuk K; Lyons Jones K
    Teratology; 2001 Nov; 64(5):252-61. PubMed ID: 11745831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodologic challenges to studying patient safety and comparative effectiveness.
    Strom BL
    Med Care; 2007 Oct; 45(10 Supl 2):S13-5. PubMed ID: 17909371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health authorities and drug utilization studies.
    Garcia Alonso F; Scott AI; Stika L; Westerholm B
    WHO Reg Publ Eur Ser; 1993; 45():147-67. PubMed ID: 8442843
    [No Abstract]   [Full Text] [Related]  

  • 6. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research challenges: overview of epidemiological study designs.
    Bombardier C
    J Rheumatol Suppl; 1988 Oct; 17():5-8. PubMed ID: 3204620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW; Fraunfelder FT
    Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing surveillance versus clinical trials: which benefits the patient?
    Lawson DH
    Cardiology; 1994; 85 Suppl 1():18-23. PubMed ID: 7743530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated support for pharmacovigilance: a proposed system.
    Bright RA; Nelson RC
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Privacy and drug surveillance: a study of the viewpoints of medication users].
    de Wit ME; Stricker BH; Porsius AJ
    Ned Tijdschr Geneeskd; 1996 Oct; 140(40):1989-92. PubMed ID: 8965928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M; Reich L; Gerrits CM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piroxicam in recent epidemiologic studies.
    Bortnichak EA; Sachs RM
    Am J Med; 1986 Nov; 81(5B):44-8. PubMed ID: 3491542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
    Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 20. The ethical issues of the postmarketing surveillance of drug teratogenicity in Hungary.
    Czeizel AE
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):635-9. PubMed ID: 11980253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.